MedTrace Logo

RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

NCT00219310 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2012-04-27

No results posted yet for this study

Summary

This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.

Conditions

  • Recurrent Genital Herpes (RGH)

Interventions

DRUG

Famciclovir

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2005-06-30
Completion
2005-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219310 on ClinicalTrials.gov